Peptide profile
Tirzepatide
Dual GIP/GLP-1 receptor agonist
Compare Tirzepatide with other peptides →Summary
A helper that works two ways to support weight loss and steady blood sugar.
- Typical dose
- 2.5-15mg Once weekly
- Route
- Subcutaneous
- Cycle length
- Ongoing
- Evidence
- Limited human data
Mechanism
How it works
Tirzepatide works like a two-key ignition system — activating both GIP and GLP-1 receptors for more powerful metabolic control than activating just one.
Dual GIP and GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, delays gastric emptying, and promotes satiety.
Reported in research
Benefits
- Helps you lose more weight than semaglutide
- Keeps blood sugar steady for people with type 2 diabetes
- Lowers signs of heart trouble
- You only take it once a week
Context, not a prescription
Dosing
- Typical range
- 2.5-15mg Once weekly (Subcutaneous)
- Cycle length
- Ongoing
Safety
Side effects & contraindications
Possible side effects
- Nausea (up to 33%)
- Diarrhea (23%)
- Vomiting (12%)
- Constipation
- Pancreatitis
- Gallbladder disease
- Severe allergic reaction
Contraindications
- Personal/family history of medullary thyroid carcinoma
- MEN-2 syndrome
- Pregnancy or breastfeeding
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Big weight loss (15-20% of your body weight), better blood sugar, and less hunger.
How it works
Think of a car that needs two keys to start. Tirzepatide turns both switches on. That gives more powerful control than just one.
It connects with two switches (GIP and GLP-1) in your pancreas, brain, and gut. Together they manage your blood sugar and hunger.
What to expect
You feel less hungry within a day. The strongest effect comes in 12-16 weeks.
- Week 1: You feel less hungry. Your tummy might feel a little upset.
- Weeks 4-8: You keep losing weight. Your blood sugar gets better.
- Weeks 12-24: You see the most weight loss and the best body changes.
Good to know
- Start with the smallest amount (2.5mg)
- Eat smaller meals with less fat
- Slowly raise the dose over 4 weeks
- Drink plenty of water
Staying safe
- Feeling sick to your stomach (up to 33%)
- Loose poop (23%)
- Throwing up (12%)
- Trouble pooping
Avoid if you have:
- People with a family history of a certain thyroid cancer
- People with a condition called MEN-2 syndrome
- People who are pregnant or breastfeeding
Mechanism of action
Dual GIP and GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, delays gastric emptying, and promotes satiety.
Binds to GIP and GLP-1 receptors on pancreatic beta cells, brain, and gut to coordinate glucose and appetite regulation.
Pharmacodynamics
Appetite suppression within 24 hours; maximum effect by 12-16 weeks.
Significant weight loss (15-20% of body weight), improved HbA1c, reduced hunger.
Timeline
- Week 1: Initial appetite reduction and possible nausea.
- Weeks 4-8: Progressive weight loss and glucose improvement.
- Weeks 12-24: Maximum weight loss and metabolic benefits.
Comparisons
- Tirzepatide — effectiveness Very High, safety Good, cost $$$, Easy to use
- Semaglutide — effectiveness Very High, safety Good, cost $$$, Easy to use
Adverse effects
Common:
- Nausea (up to 33%)
- Diarrhea (23%)
- Vomiting (12%)
- Constipation
Rare:
- Pancreatitis
- Gallbladder disease
- Severe allergic reaction
Contraindications & risk mitigation
Contraindicated in:
- Personal/family history of medullary thyroid carcinoma
- MEN-2 syndrome
- Pregnancy or breastfeeding
- Start at lowest dose (2.5mg)
- Eat smaller, low-fat meals
- Gradual dose escalation over 4 weeks
- Stay hydrated
Qué hace
Gran pérdida de peso (15-20% de tu peso corporal), mejor azúcar en sangre y menos hambre.
Cómo funciona
Imagina un coche que necesita dos llaves para arrancar. La tirzepatida enciende ambos interruptores. Eso da un control más potente que usar solo uno.
Se conecta con dos interruptores (GIP y GLP-1) en tu páncreas, cerebro e intestino. Juntos regulan tu azúcar en sangre y el hambre.
Qué esperar
Notarás menos hambre en un día. El efecto más fuerte se alcanza en 12-16 semanas.
- Semana 1: Notarás menos hambre. Tu estómago podría sentirse un poco molesto.
- Semanas 4-8: Sigues perdiendo peso. Tu azúcar en sangre mejora.
- Semanas 12-24: Observas la mayor pérdida de peso y los mejores cambios en tu cuerpo.
Bueno saber
- Comenzar con la cantidad más pequeña (2,5 mg)
- Comer porciones más pequeñas con menos grasa
- Subir la dosis lentamente durante 4 semanas
- Beber mucha agua
Manteniéndose seguro
- Sentirse con náuseas (hasta un 33%)
- Diarrea (23%)
- Vómitos (12%)
- Dificultad para ir al baño
Evitar si tienes:
- Personas con antecedentes familiares de cierto tipo de cáncer de tiroides
- Personas con una condición llamada síndrome MEN-2
- Personas que están embarazadas o en periodo de lactancia
Mecanismo de acción
Agonista dual de receptores GIP y GLP-1 que aumenta la secreción de insulina, reduce el glucagón, retrasa el vaciamiento gástrico y promueve la saciedad.
Se une a los receptores GIP y GLP-1 en las células beta pancreáticas, el cerebro y el intestino para coordinar la regulación de la glucosa y el apetito.
Farmacodinamia
Supresión del apetito en las primeras 24 horas; efecto máximo a las 12-16 semanas.
Pérdida de peso significativa (15-20% del peso corporal), mejora de la HbA1c, reducción del hambre.
Cronología
- Semana 1: Reducción inicial del apetito y posibles náuseas.
- Semanas 4-8: Pérdida de peso progresiva y mejora de la glucosa.
- Semanas 12-24: Máxima pérdida de peso y beneficios metabólicos.
Comparaciones
- Tirzepatida — efectividad Muy Alta, seguridad Buena, costo $$$, Fácil de usar
- Semaglutida — efectividad Muy Alta, seguridad Buena, costo $$$, Fácil de usar
Efectos adversos
Comunes:
- Náuseas (hasta un 33%)
- Diarrea (23%)
- Vómitos (12%)
- Estreñimiento
Raros:
- Pancreatitis
- Enfermedad de la vesícula biliar
- Reacción alérgica grave
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Antecedentes personales o familiares de carcinoma medular de tiroides
- Síndrome MEN-2
- Embarazo o lactancia
- Comenzar con la dosis más baja (2,5 mg)
- Consumir comidas más pequeñas y bajas en grasa
- Aumento gradual de la dosis durante 4 semanas
- Mantenerse hidratado
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- Ongoing
FAQ
Common questions
Is tirzepatide better than semaglutide?
Clinical trials show tirzepatide produces significantly greater weight loss and better glycemic control than semaglutide at equivalent doses.
What is the SURPASS trial result?
The SURPASS trials demonstrated 15-20% body weight reduction in patients with type 2 diabetes.
What is the evidence level?
This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.
Research
Research & sources
Current evidence for Tirzepatide is rated as Limited human data. Limited human data is available.
- 1. Tirzepatide vs semaglutide (SURPASS-2) (2021) — DOI:10.1056/NEJMoa2107519
- 2. SURMOUNT-1 weight loss (2022) — DOI:10.1056/NEJMoa2206038
- 3. Tirzepatide vs semaglutide (SURPASS-2) (2021)
- 4. SURMOUNT-1 weight loss (2022)